This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
69
Patients will undergo on the same day: * 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient); * standard assessment of clonal and organ disease; * echocardiography; * cardiac magnetic resonance. All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
RECRUITINGEvaluation of the prognostic relevance of advanced imaging variables.
\- for CMR: T1, T2, ECV, indexed volumes, mass, ejection fraction (EF);
Time frame: 12 months after diagnosis
Evaluation of the prognostic relevance of advanced imaging variables.
\- for echocardiography: left ventricular wall thickness (mLVW), EF, 2D-GLS, midwall fractional shortening (mFS), and stroke volume index (SVI);
Time frame: 12 months after diagnosis
Evaluation of the prognostic relevance of advanced imaging variables.
\- for F-PET: myocardial uptake score.
Time frame: 12 months after diagnosis
Evaluation of advanced imaging variables in response assessment.
The same variables considered at baseline will be measured 6 months after initiation of chemotherapy targeting the amyloid plasma cell clone. Changes in these variables compared to baseline will be considered.
Time frame: 6 months after initiation of chemotherapy targeting the amyloid plasma cell clone
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.